Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Details)

v3.21.2
Acquisition of Pelican Therapeutics (Details) - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2016
May 31, 2016
Mar. 31, 2018
Sep. 30, 2021
Dec. 31, 2020
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Pelican Therapeutics, Inc.                
Acquisition of Pelican Therapeutics                
Ownership interest in subsidiary       85.00% 85.00% 85.00% 80.00%  
Pelican Therapeutics, Inc.                
Acquisition of Pelican Therapeutics                
Percentage of voting interests acquired in acquisition               80.00%
Cash consideration     $ 200,000          
Percentage of non-controlling interest acquired       20.00%        
Pelican Therapeutics, Inc. | Grant revenue                
Acquisition of Pelican Therapeutics                
Amount awarded from CPRIT grant   $ 15,200,000            
Pelican Therapeutics, Inc. | Grant revenue | Maximum                
Acquisition of Pelican Therapeutics                
Amount awarded from CPRIT grant $ 15,200,000              
Pelican Therapeutics, Inc. | Stockholders                
Acquisition of Pelican Therapeutics                
Cash consideration     $ 300,000          
Pelican Therapeutics, Inc. | Certain Directors                
Acquisition of Pelican Therapeutics                
Percentage of milestone payments that will be paid to related parties     22.70%